IL159725A0 - Pharmaceutical compositions containing benzimidazole derivatives - Google Patents
Pharmaceutical compositions containing benzimidazole derivativesInfo
- Publication number
- IL159725A0 IL159725A0 IL15972502A IL15972502A IL159725A0 IL 159725 A0 IL159725 A0 IL 159725A0 IL 15972502 A IL15972502 A IL 15972502A IL 15972502 A IL15972502 A IL 15972502A IL 159725 A0 IL159725 A0 IL 159725A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- benzimidazole derivatives
- containing benzimidazole
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/901,942 US6645988B2 (en) | 1996-01-04 | 2001-07-09 | Substituted benzimidazole dosage forms and method of using same |
PCT/US2002/021368 WO2003009846A1 (en) | 2001-07-09 | 2002-07-08 | Novel substituted benzimidazole dosage forms and method of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
IL159725A0 true IL159725A0 (en) | 2004-06-20 |
Family
ID=25415102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15972502A IL159725A0 (en) | 2001-07-09 | 2002-07-08 | Pharmaceutical compositions containing benzimidazole derivatives |
Country Status (15)
Country | Link |
---|---|
US (2) | US6645988B2 (xx) |
EP (2) | EP2201952A1 (xx) |
JP (1) | JP2004521955A (xx) |
KR (1) | KR20040047771A (xx) |
CN (1) | CN1551768A (xx) |
AU (1) | AU2002330863B2 (xx) |
BR (1) | BR0210971A (xx) |
CA (1) | CA2453117C (xx) |
EA (1) | EA200400154A1 (xx) |
IL (1) | IL159725A0 (xx) |
MX (1) | MXPA04000223A (xx) |
NO (1) | NO20040072L (xx) |
PL (1) | PL367272A1 (xx) |
WO (1) | WO2003009846A1 (xx) |
ZA (1) | ZA200400241B (xx) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6537525B1 (en) * | 1997-01-29 | 2003-03-25 | Douglas H. West | Medicated chewing-gum |
WO1999053918A1 (fr) * | 1998-04-20 | 1999-10-28 | Eisai Co., Ltd. | Compositions stabilisees contenant des composes du type benzimidazole |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
DK1222922T3 (da) | 1999-10-20 | 2007-12-03 | Eisai R&D Man Co Ltd | Fremgangsmåde til stabilisering af benzimidazolforbindelser |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
AU2001279284A1 (en) * | 2000-07-05 | 2002-01-14 | Capricorn Pharma, Inc | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US20040081700A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Dose titratable liquid dosage forms of acid labile drugs |
US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
US20040151759A1 (en) * | 2002-08-16 | 2004-08-05 | Douglas Cleverly | Non-animal product containing veterinary formulations |
US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
US20060135406A1 (en) * | 2002-10-14 | 2006-06-22 | Sabina Glozman | Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion |
IL152289A0 (en) * | 2002-10-14 | 2003-05-29 | Vectabiotics Ltd | Method and composition for inhibiting h.pylori infection in a mammalian tissue |
SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
TW200503783A (en) * | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
US8802139B2 (en) * | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
DE602004025113D1 (de) * | 2003-07-11 | 2010-03-04 | Astrazeneca Ab | Feste zusammensetzung mit einem protonenpumpenhemmer |
US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AR045062A1 (es) * | 2003-07-18 | 2005-10-12 | Santarus Inc | Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas |
AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
WO2005021056A1 (en) * | 2003-08-21 | 2005-03-10 | Cns, Inc. | Effervescent delivery system |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
AU2003272081A1 (en) * | 2003-09-25 | 2005-04-11 | Natco Pharma Limited | Enteric soft gelatin capsule containing esomeprazole and method of preparation |
TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
EP1682087A1 (en) * | 2003-11-07 | 2006-07-26 | Takeda Pharmaceutical Company Limited | Chewable tablet |
US20070155780A1 (en) * | 2004-04-15 | 2007-07-05 | Hitoshi Nakata | Stabilized composition containing 4-amino-5-chloro-n-[(1r, 3r, 5s)-8-methyl-8-azabicyclo[3.2.1]oct-3-y1]-2-[1-methylbut-2-ynyloxy]benzamide |
WO2005115474A1 (en) * | 2004-05-25 | 2005-12-08 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AU2005331781C1 (en) * | 2004-05-25 | 2013-04-04 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion |
US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
WO2006011159A2 (en) * | 2004-06-21 | 2006-02-02 | Torrent Pharmaceuticals Limited | Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US20060046998A1 (en) * | 2004-08-25 | 2006-03-02 | Fairfield Clinical Trials, Llc | Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease |
DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
EP1799190A1 (en) * | 2004-10-05 | 2007-06-27 | Altana Pharma AG | Oral pharmaceutical preparation for proton pump antagonists |
US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
WO2006116582A2 (en) * | 2005-04-26 | 2006-11-02 | The Curators Of The University Of Missouri | Pharmaceutical compositions comprising a substituted benzimidazole, buffering agent and vitamin b12 |
US20080194639A1 (en) * | 2005-05-04 | 2008-08-14 | Paula Fernstrom | Proton Pump Inhibitors in the Treatment of Sleep Disturbance Due to Silent Gastroesophageal Reflux |
US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
FR2885526B1 (fr) * | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
US20100086572A1 (en) * | 2005-05-13 | 2010-04-08 | Rajneesh Taneja | Rational ppi dosage forms |
CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
CA2629904C (en) | 2005-11-28 | 2018-07-10 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
SG184754A1 (en) * | 2005-12-28 | 2012-10-30 | Takeda Pharmaceutical | Controlled release solid preparation |
US20090104264A1 (en) * | 2005-12-28 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Controlled release solid preparation |
CA2648280C (en) * | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
CH698658B1 (de) * | 2006-04-24 | 2009-09-30 | Mepha Ag | Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole. |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
WO2008002529A2 (en) * | 2006-06-26 | 2008-01-03 | Capricorn Pharma, Inc. | Orally disintegrating layered compositions |
US20070298105A1 (en) * | 2006-06-27 | 2007-12-27 | Hwang Stephen S | Methods of treating conditions by sustained release administration of benzimidazole derivatives |
DK2046334T3 (da) | 2006-07-25 | 2014-08-25 | Vecta Ltd | Sammensætninger og fremgangsmåder til at hæmme mavesyresekretion ved at anvende derivater af små dicarboxylsyrer i kombination med PPI |
PT2049123E (pt) | 2006-08-03 | 2013-03-06 | Horizon Pharma Ag | Tratamento de doença reumatóide com glucocorticóide de libertação retardada |
CN101134036B (zh) * | 2006-08-29 | 2013-05-01 | 信谊药厂 | 含有雷贝拉唑和碳酸氢钠的制剂及其制备方法 |
EP2068841B1 (en) * | 2006-10-05 | 2018-09-26 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
WO2008057802A2 (en) * | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
US20080166423A1 (en) * | 2007-01-06 | 2008-07-10 | Renjit Sundharadas | Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
US20110046079A1 (en) * | 2008-01-16 | 2011-02-24 | Mullin James M | Use of Proton Pump Inhibitors as Drug Delivery Adjuvants |
CA2716080C (en) | 2008-02-20 | 2016-12-13 | Targia Pharmaceuticals | Cns pharmaceutical compositions and methods of use |
WO2009105568A1 (en) | 2008-02-20 | 2009-08-27 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
EP2257220B1 (en) * | 2008-03-13 | 2017-06-14 | Liebel-Flarsheim Company LLC | Multi-function, foot-activated controller for imaging system |
US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
US20090280175A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Proton Pump Inhibitor Tablets |
EP2344139A1 (en) | 2008-09-09 | 2011-07-20 | AstraZeneca AB | Method for delivering a pharmaceutical composition to patient in need thereof |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
CA2749646A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
CN101836983A (zh) * | 2009-03-17 | 2010-09-22 | 北京利乐生制药科技有限公司 | 一种含有兰索拉唑镁的药物制剂及其制备方法 |
CN101843600A (zh) * | 2009-03-23 | 2010-09-29 | 杭州锐思医药科技有限公司 | 质子泵抑制剂速释胶囊 |
US20110008432A1 (en) * | 2009-06-25 | 2011-01-13 | Pozen Inc. | Method for Treating a Patient in Need of Aspirin Therapy |
EA201290026A1 (ru) | 2009-06-25 | 2012-07-30 | Астразенека Аб | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) |
EP3466438A1 (en) | 2009-08-03 | 2019-04-10 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
CN101711753B (zh) * | 2009-10-16 | 2013-06-19 | 扬子江药业集团四川海蓉药业有限公司 | 兰索拉唑固体制剂的制备方法 |
GB2475291B (en) | 2009-11-12 | 2012-03-28 | Kraft Foods R & D Inc | Beverage preparation machines |
EP2501383A4 (en) * | 2009-11-20 | 2013-06-26 | Handa Pharmaceuticals Llc | ORAL FORMULATION FOR DEXLANDSOPRAZOLE |
WO2011112229A2 (en) * | 2010-03-10 | 2011-09-15 | Incube Labs, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8562589B2 (en) | 2009-12-24 | 2013-10-22 | Rani Therapeutics, Llc | Swallowable drug delivery device and method of delivery |
EA024050B1 (ru) | 2010-04-23 | 2016-08-31 | С-БИОТЕК ХОЛДИНГ АпС | Твердая фармацевтическая композиция для нейтрализации желудочной кислоты |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8764733B2 (en) | 2010-12-23 | 2014-07-01 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9149617B2 (en) | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
CN102532610B (zh) * | 2011-12-23 | 2014-03-12 | 中山市康乃欣生物医疗科技有限公司 | 一种病理包埋剂及其制备方法和应用 |
BR112014016085A8 (pt) | 2011-12-28 | 2017-07-04 | Pozen Inc | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico |
CN102688196B (zh) * | 2012-05-21 | 2014-02-19 | 杭州华东医药集团新药研究院有限公司 | 一种含有奥美拉唑的颗粒及其制备方法 |
RU2501549C1 (ru) | 2012-08-30 | 2013-12-20 | Авва Девелопмент Лтд | Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни |
US9623047B2 (en) | 2012-12-27 | 2017-04-18 | Photo Finish Supplements, Llc | Composition and method for improving gastrointestinal health of equine |
JP6443891B2 (ja) * | 2014-01-31 | 2018-12-26 | 塩野義製薬株式会社 | 徐放性製剤 |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016092387A1 (en) * | 2014-12-12 | 2016-06-16 | Jagadeesh Induru | Powder combinations to get in-situ sponge/patch -gel/sol formulations |
US11590165B2 (en) * | 2014-12-17 | 2023-02-28 | Bausch Health Companies Inc. | Formulations of calcium and phosphate for oral inflammation |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
EP3380085B1 (de) * | 2015-11-27 | 2021-01-13 | Symrise AG | Orale zubereitungen mit omeprazol oder pantoprazol |
WO2017218894A1 (en) | 2016-06-16 | 2017-12-21 | Cutispharma, Inc. | Composition and method for proton pump inhibitor suspension |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CA3033065A1 (en) | 2016-08-11 | 2018-02-15 | Adamis Pharmaceuticals Corporation | Drug compositions |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
EP3720844A4 (en) | 2017-12-08 | 2021-08-11 | Adamis Pharmaceuticals Corporation | MEDICINAL COMPOSITIONS |
CN108159059A (zh) * | 2017-12-15 | 2018-06-15 | 哈尔滨珍宝制药有限公司 | 一种包含埃索美拉唑钠的药物组合物及其制备方法 |
KR102080023B1 (ko) * | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
RU2694527C1 (ru) * | 2018-02-06 | 2019-07-16 | Шмуэль Борис Левит | Комбинация для регенеративной терапии больных сахарным диабетом 1 типа |
US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
US10751333B1 (en) * | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
JP2022541948A (ja) * | 2019-07-26 | 2022-09-28 | チョン クン ダン ファーマシューティカル コーポレイション | エソメプラゾール及び炭酸水素ナトリウムを含む安定した薬学的組成物 |
TW202126301A (zh) | 2019-10-04 | 2021-07-16 | 愛爾蘭商席歐拉斯製藥有限公司 | 小兒懸浮調配物 |
KR102573842B1 (ko) * | 2020-02-21 | 2023-09-01 | 주식회사 종근당 | 방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물 |
KR102276547B1 (ko) * | 2020-09-04 | 2021-07-13 | 주식회사유한양행 | 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법 |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US192299A (en) | 1877-06-19 | Improvement in copying-presses | ||
US399700A (en) * | 1889-03-19 | Twine-holder | ||
US4045564A (en) | 1974-02-18 | 1977-08-30 | Ab Hassle | Benzimidazole derivatives useful as gastric acid secretion inhibitors |
US4252790A (en) * | 1974-10-23 | 1981-02-24 | Interx Research Corporation | Method for treating gastric ulcer-prone patients |
IN148930B (xx) | 1977-09-19 | 1981-07-25 | Hoffmann La Roche | |
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
JPS6043064B2 (ja) | 1979-11-28 | 1985-09-26 | ウェルファイド株式会社 | 新規イソオキサゾ−ル誘導体 |
US4359465A (en) | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
JPS57212180A (en) | 1981-06-19 | 1982-12-27 | Yoshitomi Pharmaceut Ind Ltd | Tetrahydrofuran(thiophene) compound |
US4472409A (en) | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
SE8204879D0 (sv) | 1982-08-26 | 1982-08-26 | Haessle Ab | Novel chemical intermediates |
SE8300736D0 (sv) | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
US4613497A (en) * | 1984-02-29 | 1986-09-23 | Health Products Development, Inc. | Dry, water-foamable pharmaceutical compositions |
RO88351A3 (ro) | 1984-04-26 | 1986-04-30 | Intreprinderea De Medicamente"Terapia",Ro | Compozitie pentru tratamentul afectiunilor gastroduodenale |
SE8403179D0 (sv) | 1984-06-13 | 1984-06-13 | Haessle Ab | New compounds |
JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
AU619444B2 (en) * | 1986-06-02 | 1992-01-30 | Nippon Chemiphar Co. Ltd. | 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives |
SE8604566D0 (sv) | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
US5215974A (en) | 1986-11-21 | 1993-06-01 | Aktiebolaget Hassle | Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-acid secretion related diseases |
DE3887417T2 (de) | 1987-03-25 | 1994-05-26 | Yoshitomi Pharmaceutical | Thienocinnolinverbindungen und deren verwendung als heilmittel. |
NZ224252A (en) | 1987-04-21 | 1991-09-25 | Erba Carlo Spa | An anthracycline glycoside and its preparation |
ES2043766T3 (es) | 1987-11-11 | 1994-01-01 | Pharmascience Lab | Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua. |
GB8809421D0 (en) | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
US5124158A (en) | 1988-06-30 | 1992-06-23 | The Upjohn Company | Transdermal antisecretory agents for gastrointestinal disease |
US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
WO1990003380A1 (en) | 1988-09-21 | 1990-04-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienocycloheptapyridazine compounds and medicinal uses thereof |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
EG19302A (en) | 1988-12-22 | 1994-11-30 | Haessle Ab | Compound with gastric acid inhibitory effect and process for its preparation |
SE8804628D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New compounds |
JP2694361B2 (ja) | 1989-02-09 | 1997-12-24 | アストラ アクチエボラグ | 抗菌剤 |
ATE114114T1 (de) | 1989-02-10 | 1994-12-15 | Takeda Chemical Industries Ltd | Verwendung von benzimidazol-derivaten als antibakterielle mittel. |
GB8909793D0 (en) | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
DE3931843A1 (de) * | 1989-09-23 | 1991-04-04 | Bayer Ag | Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten |
SE8903563D0 (sv) | 1989-10-26 | 1989-10-26 | Haessle Ab | A novel dissolution system |
US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
US5039132A (en) * | 1990-01-25 | 1991-08-13 | Minnesota Mining And Manufacturing Company | Method and form used for ordering custom printed products |
KR930000861B1 (ko) | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
CA2038716A1 (en) | 1990-03-28 | 1991-09-29 | Yoshio Ueda | Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide-containing preparation, stabilizing method thereof and drug stabilized thereby |
US6004989A (en) * | 1990-04-27 | 1999-12-21 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
SE9002043D0 (sv) | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
WO1991019712A1 (en) | 1990-06-20 | 1991-12-26 | Aktiebolaget Astra | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
EP0465254B1 (en) | 1990-07-06 | 1996-11-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused thiophene compounds and uses thereof |
US5041442A (en) * | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
US5232706A (en) | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
ES2024993A6 (es) | 1990-12-31 | 1992-03-01 | Genesis Para La Investigacion | Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol. |
EP0567643A4 (en) | 1991-01-16 | 1995-07-19 | Yoshitomi Pharmaceutical | PYRIDINE COMPOUND USED AS A SELECTIVE DRUG AND NEW PYRIDINE COMPOUND. |
US5244670A (en) | 1991-04-04 | 1993-09-14 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
SE502569C2 (sv) | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
NZ244301A (en) | 1991-09-20 | 1994-08-26 | Merck & Co Inc | Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds |
JPH05194225A (ja) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
US5339700A (en) | 1991-12-16 | 1994-08-23 | Isco, Inc. | Sample collector |
TW224049B (xx) | 1991-12-31 | 1994-05-21 | Sunkyong Ind Ltd | |
IS3990A (is) | 1992-04-24 | 1993-10-25 | Ab Astra | Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi |
US5504082A (en) | 1992-06-01 | 1996-04-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridine compound and pharmaceutical compostions |
FR2692146B1 (fr) | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
US5447918A (en) | 1992-07-27 | 1995-09-05 | Mccullough; Ricky W. | Gastrointestinal anti-irritant composition comprising sucralfate and methods of use |
HU226778B1 (en) | 1992-07-28 | 2009-10-28 | Astra Ab | Injection and injection kit containing omeprazole and its analogs |
JPH05194224A (ja) * | 1992-09-17 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
US5877192A (en) | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
SE9302395D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5965162A (en) | 1993-09-10 | 1999-10-12 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom |
WO1995008332A1 (en) | 1993-09-20 | 1995-03-30 | The Procter & Gamble Company | Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection |
ATE219931T1 (de) | 1993-10-12 | 2002-07-15 | Mitsubishi Pharma Corp | Darmlösliche grannulatkörner enthaltende tablette |
US5762962A (en) * | 1994-10-05 | 1998-06-09 | Warner-Lambert Company | Antacid pharmaceutical composition |
US5374730A (en) | 1993-11-04 | 1994-12-20 | Torcan Chemical Ltd. | Preparation of omeprazole and lansoprazole |
US5714505A (en) | 1994-01-05 | 1998-02-03 | Astra Aktiebolag | Method for treatment of psoriasis, by omeprazole or related compounds |
UA41995C2 (uk) * | 1994-05-06 | 2001-10-15 | Пфайзер Інк. | Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти ) |
SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
JP3350054B2 (ja) | 1994-07-08 | 2002-11-25 | アストラゼネカ・アクチエボラーグ | 複数単位の錠剤化された剤形▲i▼ |
GB2290965A (en) | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
GB9423968D0 (en) | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
SE9500422D0 (sv) | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
SE9500478D0 (sv) | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
HRP960232A2 (en) | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
SE9503102D0 (sv) | 1995-09-08 | 1995-09-08 | Astra Ab | Aseptic transfer |
EE9800116A (et) | 1995-10-17 | 1998-10-15 | Astra Pharmaceuticals Limited | Farmatseutiliselt aktiivsed kinasoliini ühendid |
SE521100C2 (sv) | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
SE512835C2 (sv) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
SE508669C2 (sv) | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
US6623759B2 (en) * | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US5766622A (en) | 1996-08-14 | 1998-06-16 | The Procter & Gamble Company | Inhibiting undesirable taste in oral compositions |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
US5885594A (en) | 1997-03-27 | 1999-03-23 | The Procter & Gamble Company | Oral compositions having enhanced mouth-feel |
US5939091A (en) | 1997-05-20 | 1999-08-17 | Warner Lambert Company | Method for making fast-melt tablets |
SE9702000D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
SE9702533D0 (sv) | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
PL195266B1 (pl) * | 1997-12-08 | 2007-08-31 | Altana Pharma Ag | Jednostka związku aktywnego nietrwałego w środowisku kwaśnym, sposób jej otrzymywania, czopki zawierające aktywny związek nietrwały w środowisku kwaśnym oraz sposób ich otrzymywania |
US6780852B2 (en) * | 1997-12-09 | 2004-08-24 | Bo E. Hedlund | Modified polysaccharides exhibiting altered biological recognition |
US5955107A (en) | 1997-12-12 | 1999-09-21 | Fmc Corporation | Pharmaceutical suspension tablet compositions |
WO1999053918A1 (fr) | 1998-04-20 | 1999-10-28 | Eisai Co., Ltd. | Compositions stabilisees contenant des composes du type benzimidazole |
US6166213A (en) | 1998-08-11 | 2000-12-26 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
WO2000026185A2 (en) * | 1998-10-30 | 2000-05-11 | The Curators Of The University Of Missouri | Omeprazole solution and method of using same |
UA72748C2 (en) | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
KR100299562B1 (ko) * | 1998-12-29 | 2001-11-22 | 우재영 | 안정성을극대화시킨5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸유도체함유미세과립 |
JP2000212180A (ja) | 1999-01-21 | 2000-08-02 | Welfide Corp | キノリン化合物 |
US6239962B1 (en) * | 1999-02-09 | 2001-05-29 | General Electric Company | ARC fault circuit breaker |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1191025B1 (en) * | 1999-06-30 | 2005-06-22 | Takeda Pharmaceutical Company Limited | Crystals of lansoprazole |
EP1210091A4 (en) * | 1999-07-12 | 2009-07-29 | Smithkline Beecham Corp | TREATMENT OF STOMACH BREEDERS |
US6268385B1 (en) * | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6262085B1 (en) * | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
DE60112306T2 (de) * | 2000-06-26 | 2006-01-12 | Lilly Icos Llc, Wilmington | Kondensierte pyrazindionderivate als pde5 inhibitore |
KR100473433B1 (ko) * | 2000-07-17 | 2005-03-08 | 마쯔시다덴기산교 가부시키가이샤 | 비수전해액 및 그것을 포함하는 비수전해액전지 및 전해콘덴서 |
US6749867B2 (en) * | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
US20020192299A1 (en) | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
US6684276B2 (en) * | 2001-03-28 | 2004-01-27 | Thomas M. Walker | Patient encounter electronic medical record system, method, and computer product |
US6608091B2 (en) * | 2001-04-20 | 2003-08-19 | Linda B. Whittall | Process for purifying 6-methoxy omeprazole |
CA2480352A1 (en) * | 2002-03-27 | 2003-10-09 | Teva Pharmaceutical Industries Ltd. | Lansoprazole polymorphs and processes for preparation thereof |
-
2001
- 2001-07-09 US US09/901,942 patent/US6645988B2/en not_active Expired - Lifetime
-
2002
- 2002-07-08 IL IL15972502A patent/IL159725A0/xx unknown
- 2002-07-08 JP JP2003515238A patent/JP2004521955A/ja active Pending
- 2002-07-08 WO PCT/US2002/021368 patent/WO2003009846A1/en active IP Right Grant
- 2002-07-08 AU AU2002330863A patent/AU2002330863B2/en not_active Ceased
- 2002-07-08 BR BR0210971-9A patent/BR0210971A/pt not_active IP Right Cessation
- 2002-07-08 MX MXPA04000223A patent/MXPA04000223A/es active IP Right Grant
- 2002-07-08 KR KR10-2004-7000345A patent/KR20040047771A/ko not_active Application Discontinuation
- 2002-07-08 EP EP10157716A patent/EP2201952A1/en not_active Withdrawn
- 2002-07-08 PL PL02367272A patent/PL367272A1/xx not_active Application Discontinuation
- 2002-07-08 CA CA2453117A patent/CA2453117C/en not_active Expired - Lifetime
- 2002-07-08 CN CNA028172493A patent/CN1551768A/zh active Pending
- 2002-07-08 EP EP02768296A patent/EP1414452A4/en not_active Withdrawn
- 2002-07-08 EA EA200400154A patent/EA200400154A1/ru unknown
-
2003
- 2003-04-18 US US10/418,410 patent/US20040048896A1/en not_active Abandoned
-
2004
- 2004-01-08 NO NO20040072A patent/NO20040072L/no not_active Application Discontinuation
- 2004-01-13 ZA ZA200400241A patent/ZA200400241B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20040047771A (ko) | 2004-06-05 |
ZA200400241B (en) | 2004-10-29 |
EA200400154A1 (ru) | 2004-06-24 |
US20040048896A1 (en) | 2004-03-11 |
NO20040072L (no) | 2005-03-08 |
WO2003009846A1 (en) | 2003-02-06 |
EP1414452A1 (en) | 2004-05-06 |
EP1414452A4 (en) | 2005-07-20 |
CA2453117C (en) | 2010-06-29 |
MXPA04000223A (es) | 2005-04-19 |
BR0210971A (pt) | 2004-08-24 |
CN1551768A (zh) | 2004-12-01 |
US20020045646A1 (en) | 2002-04-18 |
US6645988B2 (en) | 2003-11-11 |
EP2201952A1 (en) | 2010-06-30 |
AU2002330863B2 (en) | 2007-05-31 |
CA2453117A1 (en) | 2003-02-06 |
PL367272A1 (en) | 2005-02-21 |
JP2004521955A (ja) | 2004-07-22 |
AU2002330863B9 (en) | 2003-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159725A0 (en) | Pharmaceutical compositions containing benzimidazole derivatives | |
IL158041A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
HK1072200A1 (en) | Pro-micelle pharmaceutical compositions | |
EG25614A (en) | Novel pyrroles derivatives as pharmaceutical agents | |
IL175252A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
GB0111597D0 (en) | Pharmaceutical compositions | |
EP1450824A4 (en) | PHARMACEUTICAL COMPOSITION | |
IL161616A0 (en) | Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
EP1407785A4 (en) | MEDICAL COMPOSITIONS | |
HK1065944A1 (en) | Medicinal compositions | |
IL158044A0 (en) | Cyclopropylindole derivatives and pharmaceutical compositions containing the same | |
IL158300A0 (en) | Bisarylimidazol derivatives and pharmaceutical compositions containing the same | |
IL156812A0 (en) | Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same | |
IL156988A0 (en) | Pharmaceutical compositions containing epothilone derivatives | |
IL157128A0 (en) | Pharmaceutical compositions containing epothilone derivatives | |
EG24194A (en) | 5ht-a-partial agonist pharmaceutical compositions | |
HUP0303163A3 (en) | Tramadol-based pharmaceutical composition | |
HUP0400850A3 (en) | Oral pharmaceutical compositions | |
GB0117057D0 (en) | Pharmaceutical composition | |
EP1408896A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB0129117D0 (en) | Pharmaceutical composition | |
HK1068277A1 (en) | Pharmaceutical compositions comprising chelidonineor derivatives thereof | |
GB0116107D0 (en) | Pharmaceutical composition | |
GB0104752D0 (en) | Pharmaceutical compositions | |
GB0127805D0 (en) | Pharmaceutical composition |